Ignite Creation Date:
2025-12-24 @ 3:07 PM
Ignite Modification Date:
2026-01-27 @ 8:09 AM
Study NCT ID:
NCT05086692
Status:
RECRUITING
Last Update Posted:
2025-07-09
First Post:
2021-09-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Beta-only IL-2 ImmunoTherapY Study
Sponsor:
Medicenna Therapeutics, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Solid Tumor | View |
| None | Unresectable Solid Tumor | View |
| None | Clear Cell Renal Cell Carcinoma | View |
| None | Triple Negative Breast Cancer | View |
| None | Non-Small Cell Lung Cancer Squamous | View |
| None | Non-Small Cell Lung Cancer Non-squamous | View |
| None | Colorectal Cancer (MSI-H) | View |
| None | Gastric Cancer | View |
| None | Cervical Cancer | View |
| None | Basal Cell Carcinoma | View |
| None | Bladder Cancer | View |
| None | Merkel Cell Carcinoma | View |
| None | Squamous Cell Carcinoma of Head and Neck | View |
| None | Cutaneous Squamous Cell Carcinoma | View |
| None | Pleural Mesothelioma | View |
| None | Esophageal Cancer | View |
| None | Endometrial Carcinoma | View |
| None | Solid Tumor | View |
| None | Solid Tumor, Adult | View |
| None | MSI-H Solid Malignant Tumor | View |
| None | Cancer With A High Tumor Mutational Burden | View |
| None | Epithelial Ovarian Carcinoma | View |
| None | Primary Peritoneal Cancer | View |
| None | Gastroesophageal Junction (GEJ) Cancer | View |
| None | Acral Melanoma | View |
| None | Mucosal Melanoma | View |
| None | Cutaneous Melanoma | View |
| None | DMMR Solid Malignant Tumor | View |
| None | Fallopian Tube Cancer | View |
| None | Ovarian Cancer | View |
| None | MSI-H Cancer | View |
| None | DMMR Cancer | View |
| None | Pancreas Adenocarcinoma (MSI-H) | View |
| None | Skin Cancer | View |
| None | Viral Cancer | View |
| None | Cervical Cancers | View |
| None | Endometrial Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | IL-2 | View |
| None | IL2 | View |
| None | Interleukin-2 | View |
| None | cancer | View |
| None | metastatic | View |
| None | ccRCC | View |
| None | TNBC | View |
| None | NSCLC | View |
| None | CRC | View |
| None | GEJ | View |
| None | intrahepatic | View |
| None | extrahepatic | View |
| None | MCC | View |
| None | SCCHN | View |
| None | CSCC | View |
| None | Gastroesophageal Junction | View |
| None | advanced | View |
| None | unresectable | View |
| None | MSI-H | View |
| None | dMMR | View |
| None | Microsatellite Instability-High | View |
| None | Mismatch Repair Deficient | View |
| None | PD-1 | View |
| None | immunotherapy | View |
| None | anti-PD-1 | View |
| None | BCC | View |
| None | RCC | View |
| None | HCC | View |
| None | Tumor Mutation Burden High | View |
| None | TMB-H | View |
| None | PDAC | View |